Restricted accessResearch articleFirst published online 2018-09
Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3 -Linked Achromatopsia Investigated in an Exploratory Dose-Escalation Trial
Achromatopsia is an autosomal recessively inherited congenital defect characterized by a lack of cone photoreceptor function, leading to severely impaired vision. In this clinical study, achromatopsia patients were treated with a single subretinal injection of rAAV.hCNGA3 to restore cone function. The focus of this trial was on the safety of the treatment. After surgery, patients were monitored in eight extensive visits during the first year, followed by a 4-year follow-up period with annual visits. For essential complementation of the standard ophthalmological and systemic examinations, disease-specific methods were developed to assess the safety, efficacy, and patient-reported outcomes in this trial.
Get full access to this article
View all access options for this article.
References
1.
KohlS, MarxT, GiddingsI, et al.Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel. Nat Genet, 1998; 19:257–259.
2.
KohlS, BaumannB, BroghammerM, et al.Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet, 2000; 9:2107–2116.
3.
WissingerB, GamerD, JagleH, et al.CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet, 2001; 69:722–737.
4.
Burgueno-MontanesC, Colunga CuevaM, Costales AlvarezC. A novel mutation in the CNGA3 gene responsible for incomplete achromatopsia. Arch Soc Esp Oftalmol, 2014; 89:107–109.
5.
YangP, MichaelsKV, CourtneyRJ, et al.Retinal morphology of patients with achromatopsia during early childhood: implications for gene therapy. JAMA Ophthalmol, 2014; 132:832–831.
6.
MichalakisS, MuhlfriedelR, TanimotoN, et al.Restoration of cone vision in the CNGA3–/– mouse model of congenital complete lack of cone photoreceptor function. Mol Ther, 2010; 18:2057–2063.
7.
BainbridgeJW, SmithAJ, BarkerSS, et al.Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008; 358:2231–2239.
8.
HauswirthWW, AlemanTS, KaushalS, et al.Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a Phase I trial. Hum Gene Ther, 2008; 19:979–990.
9.
MaguireAM, SimonelliF, PierceEA, et al.Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med, 2008; 358:2240–2248.
10.
JacobsonSG, CideciyanAV, RatnakaramR, et al.Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol, 2012; 130:9–24.
11.
SeitzIP, FischerD, MichalakisS, et al.rAAV8 biodistribution and shedding after subretinal injection in non-human primates. Invest Ophthalmol Vis Sci, 2016; 57:4025.
12.
VandenbergheLH, BellP, MaguireAM, et al.Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med, 2011; 3:88ra54.
13.
MichalakisS, MuhlfriedelR, TanimotoN, et al.Gene therapy restores missing cone-mediated vision in the CNGA3–/– mouse model of achromatopsia. Adv Exp Med Biol, 2012; 723:183–189.
14.
JeonCJ, StrettoiE, MaslandRH. The major cell populations of the mouse retina. J Neurosci, 1998; 18:8936–8946.
15.
SamulskiRJ, ChangLS, ShenkT. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol, 1987; 61:3096–3101.
ReichelFF, DauletbekovDL, KleinR, et al.AAV8 can induce innate and adaptive immune response in the primate eye. Mol Ther, 2017; 25:2648–2660.
18.
RobsonJG. Spatial and temporal contrast sensitivity functions of the visual system. J Opt Soc Am, 1966; 56:1141–1142.
19.
de LangeH. Research into the dynamic nature of the human fovea-cortex systems with intermittent and modulated light. II Phase shift in brightness and delay in color perception. J Opt Soc Am, 1958; 48:784–789.
20.
WernerA, SharpeLT, ZrennerE. Asymmetries in the time-course of chromatic adaptation and the significance of contrast. Vision Res, 2000; 40:1101–1113.
21.
ReganBC, ReffinJP, MollonJD. Luminance noise and the rapid determination of discrimination ellipses in colour deficiency. Vision Res, 1994; 34:1279–1299.
22.
FarnsworthD. The Farnsworth Dichotomous Test for Color Blindness, Panel D-15: Manual. New York: Psychological Corp., 1947.
23.
LisowskaJ, LisowskiL, KelbschC, et al.Development of a chromatic pupillography protocol for the first gene therapy trial in patients with CNGA3-linked achromatopsia. Invest Ophthalmol Vis Sci, 2017; 58:1274–1282.
24.
MidenaE, VujosevicS, CavarzeranF; Microperimetry Study Group. Normal values for fundus perimetry with the microperimeter MP1. Ophthalmology, 2010; 117:1571–1576, 1576.e1.
25.
McCullochDL, MarmorMF, BrigellMG, et al.ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol, 2015; 130:1–12.
26.
YaqoobZ, WuJ, YangC. Spectral domain optical coherence tomography: a better OCT imaging strategy. Biotechniques, 2005; 39:S6–13.
27.
Schmitz-ValckenbergS, HolzFG, BirdAC, et al.Fundus autofluorescence imaging: review and perspectives. Retina, 2008; 28:385–409.
28.
MangioneCM, LeePP, GutierrezPR, et al.Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol, 2001; 119:1050–1058.
29.
WilhelmB, KoegelA, KahleN, et al.How do patients rate their subjective symptoms after CNGA3 gene therapy: first application of the instrument A3-PRO. Inv Ophthalmol Vis Sci, 2017; 58:4678–4678.
30.
MaguireAM, HighKA, AuricchioA, et al.Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a Phase 1 dose-escalation trial. Lancet, 2009; 374:1597–1605.
31.
BennettJ, AshtariM, WellmanJ, et al.AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med, 2012; 4:120ra115.
32.
MichalakisS, BecirovicE, BielM. Retinal cyclic nucleotide-gated channels: from pathophysiology to therapy. Int J Mol Sci, 2018; 19.
33.
SchneppBC, ClarkKR, KlemanskiDL, et al.Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol, 2003; 77:3495–3504.
ZoborD, WernerA, StanzialF, et al.The clinical phenotype of CNGA3-related achromatopsia: pretreatment characterization in preparation of a gene replacement therapy trial. Invest Ophthalmol Vis Sci, 2017; 58:821–832.
36.
WilhelmH, PetersT, DurstW, et al. [Assessment of mesopic and contrast vision for driving licences: which cut-off values, which methods are appropriate?] Klin Monbl Augenheilkd, 2013; 230:1106–1113.
37.
KelbschC, MaedaF, LisowskaJ, et al.Analysis of retinal function using chromatic pupillography in retinitis pigmentosa and the relationship to electrically evoked phosphene thresholds. Acta Ophthalmol, 2017; 95:e261–e269.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
